309 related articles for article (PubMed ID: 37108955)
41. Azole resistance in Aspergillus species in Southern Taiwan: An epidemiological surveillance study.
Chen YC; Kuo SF; Wang HC; Wu CJ; Lin YS; Li WS; Lee CH
Mycoses; 2019 Dec; 62(12):1174-1181. PubMed ID: 31549427
[TBL] [Abstract][Full Text] [Related]
42. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
43. The Novel Monoclonal IgG
Kakoschke TK; Kleinemeier C; Knösel T; Kakoschke SC; Ebel F
J Fungi (Basel); 2023 May; 9(6):. PubMed ID: 37367559
[TBL] [Abstract][Full Text] [Related]
44. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.
Steinbach WJ; Marr KA; Anaissie EJ; Azie N; Quan SP; Meier-Kriesche HU; Apewokin S; Horn DL
J Infect; 2012 Nov; 65(5):453-64. PubMed ID: 22898389
[TBL] [Abstract][Full Text] [Related]
45. Aspergillus species intrinsically resistant to antifungal agents.
Van Der Linden JW; Warris A; Verweij PE
Med Mycol; 2011 Apr; 49 Suppl 1():S82-9. PubMed ID: 20662634
[TBL] [Abstract][Full Text] [Related]
46. Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis.
Person AK; Chudgar SM; Norton BL; Tong BC; Stout JE
J Med Microbiol; 2010 Jul; 59(Pt 7):834-838. PubMed ID: 20299503
[TBL] [Abstract][Full Text] [Related]
47. Changes in the epidemiological landscape of invasive mould infections and disease.
Lass-Flörl C; Cuenca-Estrella M
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462
[TBL] [Abstract][Full Text] [Related]
48. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
[TBL] [Abstract][Full Text] [Related]
49. Surveillance for azoles resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates.
Reichert-Lima F; Lyra L; Pontes L; Moretti ML; Pham CD; Lockhart SR; Schreiber AZ
Mycoses; 2018 Jun; 61(6):360-365. PubMed ID: 29468746
[TBL] [Abstract][Full Text] [Related]
50. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
51. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Wei XC; Zhao MF; Li X; Xiao X
Int J Antimicrob Agents; 2020 Oct; 56(4):106112. PubMed ID: 32721598
[TBL] [Abstract][Full Text] [Related]
52. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
[TBL] [Abstract][Full Text] [Related]
53. Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus.
Colley T; Sharma C; Alanio A; Kimura G; Daly L; Nakaoki T; Nishimoto Y; Bretagne S; Kizawa Y; Strong P; Rapeport G; Ito K; Meis JF; Chowdhary A
J Antimicrob Chemother; 2019 Oct; 74(10):2950-2958. PubMed ID: 31361006
[TBL] [Abstract][Full Text] [Related]
54. Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: Comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Park YJ; Lee JW
Medicine (Baltimore); 2017 Dec; 96(49):e8841. PubMed ID: 29245249
[TBL] [Abstract][Full Text] [Related]
55. Challenging fungal infections in cystic fibrosis: a case of mixed Aspergillus species infection and antifungal combination testing.
Pontes L; Reichert-Lima F; Perini Leme Giordano AL; Moretti ML; Zaninelli Schreiber A
Access Microbiol; 2024; 6(4):. PubMed ID: 38737802
[No Abstract] [Full Text] [Related]
56. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
Espinel-Ingroff A; Diekema DJ; Fothergill A; Johnson E; Pelaez T; Pfaller MA; Rinaldi MG; Canton E; Turnidge J
J Clin Microbiol; 2010 Sep; 48(9):3251-7. PubMed ID: 20592159
[TBL] [Abstract][Full Text] [Related]
57. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
58. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
[TBL] [Abstract][Full Text] [Related]
59. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.
Chandrasekar PH; Cutright JL; Manavathu EK
Diagn Microbiol Infect Dis; 2001 Dec; 41(4):211-4. PubMed ID: 11777662
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
Misra R; Malik A; Singhal S
Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
